Skip to navigation

Press Releases

MEDWELL PAYS DIVIDEND OF SPECTRAL WARRANTS

EDMONTON, Alberta – December 6, 2013 – Medwell Capital Corp. ("Medwell") (TSX-V: MWC) is pleased to announce that on December 6, 2013 it effected payment of its previously announced dividend. Shareholders of record at the close of business on November 12, 2013 received two (2) share purchase warrants of Spectral Diagnostics Inc. ("Spectral") for every one (1) common share of Medwell they hold. Each Spectral warrant entitles the holder to purchase one common share of Spectral at a price of $0.60 per share until March 2, 2014.

The dividend will result in the payout of 14,207,472 Spectral warrants, following which Medwell continues to hold 992,528 Spectral warrants.

No Spectral warrants were distributed to Medwell shareholders who are (or are deemed to be) non-residents of Canada. Non-resident Medwell shareholders were paid the cash value of the Spectral Warrants, being $0.0458 per warrant.

ON BEHALF OF THE BOARD OF DIRECTORS OF MEDWELL CAPITAL CORP.
"Kevin Giese"
President, CEO & Chairman

About Medwell Capital Corp.
Medwell Capital Corp. is a Canadian-based investment and advisory firm. For further information please visit www.medwellcapital.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  

This press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Current News

?>